Hong-Xin Zhao

A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a widely used antiretroviral regimen, but its real-world long-term safety profile in diverse populations remains incompletely characterized. We analyzed adverse drug signals from the FAERS database (2018–2025) with B/F/TAF as the primary suspected...